The changes that occur in the body after stopping the obesity drug are called Health: Up to 75% of the weight lost can be regained after stopping Ozempic

No time to read?
Get a summary

After you stop using Ozempica, a drug designed to combat type 2 diabetes and obesity, the weight you lose may come back, so you should switch to a special diet before stopping the drug. talking about it Health.

Ozempic, when used long-term (always requires medical supervision), is effective in helping obese people lose weight and improve control of type 2 diabetes.

This medication increases the time it takes for the stomach to empty, thereby reducing appetite and promoting weight loss. After discontinuation of the drug, the rate of passage of food through the gastrointestinal tract returns to normal, which can lead to a strong feeling of hunger and even an increase in the volume of food required for satiety. As a result, blood sugar and cholesterol levels rise, the lost weight comes back and blood pressure rises. Symptoms may last for weeks or months.

In a 2022 clinical study, patients were followed for 52 weeks after they stopped taking Ozempic. Participants taking semaglutide for 68 weeks lost a significant amount of weight. But 52 weeks after quitting, most regained two-thirds of the weight they lost. That’s why experts recommend that people who stop taking Ozempic develop a nutrition plan with their doctor before stopping, keep a diary to record meals, visit the doctor more often, and consider alternative medications for obesity. Sometimes people want to stop taking the medication due to side effects, in which case the dose may be adjusted to maintain the effect.

Previous scientists I learnedDrugs such as Ozempic may reduce the risk of cancer.

No time to read?
Get a summary
Previous Article

Abkhazian President supported Putin’s decision to participate in upcoming elections

Next Article

An effective drug was found against the most dangerous cancer in women. NEJM: Mirvetuximab soravtansin drug extended life expectancy in ovarian cancer by 30%